Want to see JP:7747 full AI Analyst Report?
Top Page
Asahi Intecc Co
(7747)
Select Model
Select Model
Rating:78Outperform
Price Target:
¥4,674.00
▲(19.11% Upside)
Action:Reiterated
Date:08/19/26
The score is driven primarily by strong financial performance (improving profitability, steady growth, and low leverage). Technicals are supportive with clear trend strength, though momentum indicators suggest the stock may be stretched short-term. Valuation is the main constraint due to a high P/E relative to the modest dividend yield.
Positive Factors
Revenue Growth and Profitability
Sustained revenue expansion combined with strong gross and operating margins indicates effective product economics and operating leverage. The sharp 2026 profit improvement strengthens internal funding capacity, although durability should be monitored.
Negative Factors
Uneven Free Cash Flow History
Historical free-cash-flow inconsistency suggests working-capital needs, investment cycles, or other cash demands can materially reduce earnings conversion. This may limit the reliability of internally funded growth across different operating conditions.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth and Profitability
Sustained revenue expansion combined with strong gross and operating margins indicates effective product economics and operating leverage. The sharp 2026 profit improvement strengthens internal funding capacity, although durability should be monitored.
Read all positive factors
Asahi Intecc Co (7747) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥1.07T
Dividend Yield1.2%
Average Volume (3M)951.34K
Price to Earnings (P/E)32.3
Beta (1Y)0.57
Revenue Growth21.16%
EPS Growth157.04%
CountryJP
Employees9,473
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)114.80
Shares Outstanding265,332,300
10 Day Avg. Volume923,580
30 Day Avg. Volume951,336
Financial Highlights & Ratios
PEG Ratio0.20
Price to Book (P/B)5.83
Price to Sales (P/S)6.95
P/FCF Ratio31.87
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥4,500.00Price Target Upside14.68% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)138.59
Revenue Forecast (FY)¥160.03B
Asahi Intecc Co Business Overview & Revenue Model
Company Description
Asahi Intecc Co., Ltd. is a global enterprise dedicated to the research, manufacturing, and distribution of advanced medical devices. Its market reach extends across Japan, the United States, Europe, the Middle East, and China, with a significant ...
How the Company Makes Money
Asahi Intecc primarily makes money by manufacturing and selling medical devices and related components used in minimally invasive procedures. A major revenue stream comes from the sale of proprietary guidewires and catheter/vascular-intervention a...
Asahi Intecc Co Financial Statement Overview
Summary
Income Statement
86
Very Positive
Balance Sheet
92
Very Positive
Cash Flow
78
Positive
| Breakdown | TTM | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 136.58B | 145.42B | 120.03B | 107.55B | 90.10B | 77.75B |
| Gross Profit | 95.76B | 99.39B | 78.23B | 66.11B | 56.26B | 49.24B |
| EBITDA | 50.42B | 53.98B | 29.01B | 31.73B | 26.76B | 23.34B |
| Net Income | 30.63B | 32.08B | 12.74B | 15.81B | 13.11B | 10.86B |
Balance Sheet | ||||||
| Total Assets | 203.73B | 218.28B | 193.19B | 191.61B | 172.64B | 155.13B |
| Cash, Cash Equivalents and Short-Term Investments | 59.80B | 64.26B | 54.20B | 38.66B | 36.88B | 32.32B |
| Total Debt | 7.23B | 8.66B | 11.52B | 8.20B | 15.87B | 13.22B |
| Total Liabilities | 36.57B | 43.92B | 41.83B | 39.65B | 38.34B | 33.99B |
| Stockholders Equity | 166.23B | 173.41B | 150.56B | 151.22B | 132.31B | 119.46B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 31.71B | 32.45B | 24.83B | 6.85B | 9.32B |
| Operating Cash Flow | 0.00 | 40.09B | 40.54B | 34.71B | 19.14B | 17.30B |
| Investing Cash Flow | 0.00 | -11.74B | -13.43B | -21.22B | -15.13B | -18.70B |
| Financing Cash Flow | 0.00 | -19.97B | -8.11B | -13.88B | -2.34B | 11.37B |
Asahi Intecc Co Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
83 Outperform | ¥159.01B | 23.43 | ― | 2.73% | 9.94% | 10.50% | |
80 Outperform | ¥3.84T | 23.07 | 9.19% | 1.39% | 14.05% | 31.94% | |
78 Outperform | ¥1.07T | 32.34 | 19.68% | 1.36% | 21.16% | 157.04% | |
70 Outperform | ¥2.38T | 30.80 | 8.94% | 1.65% | 7.80% | -27.73% | |
66 Neutral | ¥270.55B | 117.99 | 0.98% | 2.66% | 14.87% | -55.19% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | ¥257.12B | 18.04 | 5.37% | 2.03% | 2.68% | 144.20% |
* Healthcare Sector Average
JP:7747
Asahi Intecc Co
3,924.00
1,438.15
57.85%
JP:4543
Terumo
2,572.00
-56.05
-2.13%
JP:7716
Nakanishi
3,260.00
1,208.82
58.93%
JP:8086
Nipro
1,572.50
99.13
6.73%
JP:7733
Olympus
2,133.00
431.04
25.33%
JP:7730
Mani, Inc.
1,607.00
365.84
29.48%
Asahi Intecc Co Corporate Events
Asahi Intecc Reports FY2026 Results and Issues FY2027 Outlook
Aug 14, 2026
Asahi Intecc Co. released its consolidated financial results for the fiscal year ended June 2026, providing investors with an overview of recent performance and profitability. The disclosure serves as a basis for assessing the company’s curr...
Asahi Intecc Delivers Record Earnings and Doubles Dividend on Strong FY2026 Performance
Aug 14, 2026
Asahi Intecc Co., Ltd. is a Japanese medical device maker listed in Tokyo and Nagoya, known for its advanced catheter and guide wire products used in minimally invasive cardiovascular treatments worldwide. The company targets high-growth intervent...
Asahi Intecc Doubles Dividend as It Tightens 35% Payout Policy
Aug 14, 2026
Asahi Intecc Co., Ltd. said its board has approved a proposal to distribute a year‑end dividend for the fiscal year ended June 30, 2026, with a dividend of 48.24 yen per share and a total payout of 5,533 million yen, sourced from retained ea...
Asahi Intecc Secures Japan Exclusivity for Nuvascular Aneurysm Device
Aug 14, 2026
Asahi Intecc has signed an exclusive distribution agreement with California‑based Nuvascular, Inc. to sell its intrasaccular occlusion device, HARBOR, in Japan once regulatory approval is obtained. The device, currently in clinical trials fo...
Asahi Intecc Updates 2030 Plan to Drive Sustainable Global Growth
Aug 14, 2026
Asahi Intecc has outlined an updated medium-term management plan, titled “Building the Future 2030 ~Unlocking Sustainable Growth~,” signaling a strategic push to refine its numerical targets and strengthen its long-term growth trajecto...
Asahi Intecc Raises 2030 Plan and Long-Term Profit Targets on Strong Performance
Aug 14, 2026
Asahi Intecc has revised upward the financial targets in its medium-term management plan, Building the Future 2030, after outperforming initial assumptions on sales growth and profitability. Strong market share gains across regions, productivity i...
Asahi Intecc Reinstates Chairman Masahiko Miyata as Co-Representative Director
Jun 12, 2026
Asahi Intecc has appointed chairman Masahiko Miyata as Representative Director and Chairman, effective July 1, 2026, adding him as a second representative director alongside President and CEO Kenji Miyata. The decision follows confirmation of his ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.